Healthleap secures $38 million for hospital risk-screening AI

Healthleap raises $38 million for hospital patient-risk screening

Healthleap, a startup developing AI software that reviews hospital patient records for potential undiagnosed conditions, has raised $38 million in seed and Series A financing. The funding consists of an $8 million seed round co-led by Sequoia Capital and First Round Capital and a $30 million Series A led by Hummingbird Ventures. The company did not disclose its valuation.

Founded in South Africa in 2022 by siblings Jemima and Josiah Meyer, Healthleap initially offered a clinical nutrition product for dietitians. It later shifted to a broader platform designed to identify inpatients who may warrant closer review for conditions including malnutrition and delirium.

Healthleap says its platform is now deployed at more than 50 hospitals. Its customers include Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist and Emory Healthcare. Josiah Meyer said the company expanded from three hospital partners to more than 50 in the past year, while revenue grew by more than tenfold, without disclosing revenue figures.

Language models combine notes with structured clinical data

The platform connects with a hospital electronic health record system. It uses language models to extract information from clinicians’ written notes, including references to poor appetite, recent weight loss, muscle loss and difficulty swallowing. Healthleap combines those signals with structured data such as laboratory results, vital signs, weights, medications, diet orders and diagnoses.

Healthleap analyzes each adult inpatient record overnight and writes a risk score into the care team’s existing workflow each morning. A dashboard provides additional information about patient trends. The company emphasizes that the software does not diagnose patients; it highlights patients for additional review by care teams.

Malnutrition is one of the first conditions addressed by the platform. Research cited by the company suggests that 20% to 50% of hospital inpatients are malnourished, while studies have associated malnutrition with longer stays, impaired wound healing, infections, complications and higher morbidity and mortality.

Expansion plans include additional conditions and care settings

Healthleap has also developed programs aimed at identifying aspiration pneumonia, pressure ulcers and readmission risk for congestive heart failure. Meyer said these programs remain under further clinical validation. The company ultimately aims to support more than 40 major health conditions and to expand into outpatient and home-care settings.

The startup sells three-year contracts priced by a hospital’s licensed bed count and also uses outcome-based pricing. Healthleap says it contractually commits to delivering multiples of the contract price based on hard return on investment validated by hospital finance teams. It reports that every customer has seen at least a 5x hard ROI, with some reporting more than 20x annual total ROI.

At the Hospital of the University of Pennsylvania, Healthleap says its malnutrition program produced $23.8 million in annualized financial impact: $6.3 million in additional reimbursement and $17.5 million from shorter stays. The new capital is intended for engineering, product, sales and customer success. For hospital buyers, the practical question is whether risk alerts integrate into clinical workflows and whether clinical validation and locally verified outcomes justify broader deployment.